The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild‐to‐moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double‐blind, placebo‐controlled trial

Abstract Background Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and neuroproliferative properties in cellular and anim...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Christopher L.H. Chen, Purabi Reang Sharma, Boon Yeow Tan, Casuarine Low, Narayanaswamy Venketasubramanian
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2019-01-01
Edice:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Témata:	MLC901 Clinical trial Alzheimer's disease Disease progression Neuroaid II
On-line přístup:	https://doi.org/10.1016/j.trci.2018.12.001
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!